NCT03094845 is a Phase 2 clinical trial of hdmASIT+TM in House Dust Mite Allergy, sponsored by ASIT Biotech S.A..

Who is sponsoring NCT03094845?

NCT03094845 is sponsored by ASIT Biotech S.A..

What drugs are being tested in NCT03094845?

Interventions in NCT03094845: Placebo solution, hdmASIT+TM.

What condition does NCT03094845 study?

NCT03094845 studies House Dust Mite Allergy.

Is NCT03094845 still recruiting?

NCT03094845 is currently completed. Last updated 29 March 2017.

Last reviewed 2017-03-29 · How we verify

NCT03094845

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients

Completed Phase 2 Last updated 29 March 2017

What this trial tests

Phase 2 trial testing Placebo solution in House Dust Mite Allergy in 36 participants. Completed in 23 January 2017.

Timeline

28 September 2016

Primary endpoint
12 January 2017

23 January 2017

Quick facts

Lead sponsor	ASIT Biotech S.A.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	28 September 2016
Primary completion	12 January 2017
Estimated completion	23 January 2017
Sites	1 location across Germany

Drugs / interventions tested

Placebo solution
hdmASIT+TM — full drug profile →

Conditions studied

House Dust Mite Allergy — all drugs for House Dust Mite Allergy →

Sponsor

ASIT Biotech S.A. — full company profile →

Who can join

Adults 18 to 64, any sex, with House Dust Mite Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with house dust mite-induced allergic rhinoconjunctivitis compared to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for House Dust Mite Allergy

Currently open trials in the same condition.

NCT06920771 — A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,0 · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03094845 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ASIT Biotech S.A.
Last refreshed: 29 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing